Benitec Biopharma (BNTC) Revenue & Revenue Breakdown
Benitec Biopharma Revenue Highlights
00
Main Segment (Y)
License
Main Geography (Y)
License
Benitec Biopharma Revenue by Period
Benitec Biopharma Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | -100.00% |
| 2024-06-30 | $216.00K | 188.00% |
| 2023-06-30 | $75.00K | 2.74% |
| 2022-06-30 | $73.00K | 23.73% |
| 2021-06-30 | $59.00K | -39.18% |
| 2020-06-30 | $97.00K | -99.14% |
| 2019-06-30 | $11.32M | 2384.77% |
| 2018-06-30 | $455.45K | 1.14% |
| 2017-06-30 | $450.31K | 29.96% |
| 2016-06-30 | $346.51K | -58.21% |
| 2015-06-30 | $829.13K | -18.53% |
| 2014-06-30 | $1.02M | 86.49% |
| 2013-06-30 | $545.73K | - |
Benitec Biopharma generated - in revenue during NA 2025, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Benitec Biopharma Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | - | -100.00% |
| 2025-06-30 | $556.00K | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-12-31 | - | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $6.00K | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $7.00K | -87.04% |
| 2023-03-31 | $54.00K | 285.71% |
| 2022-12-31 | $14.00K | -97.03% |
| 2022-09-30 | $472.00K | 100.00% |
| 2022-06-30 | - | -100.00% |
| 2022-03-31 | $48.00K | 92.00% |
| 2021-12-31 | $25.00K | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $2.00K | 100.00% |
| 2021-03-31 | $1.00K | - |
| 2020-12-31 | $1.00K | -98.18% |
| 2020-09-30 | $55.00K | -237.50% |
| 2020-06-30 | $-40.00K | -242.86% |
| 2020-03-31 | $28.00K | -63.64% |
| 2019-12-31 | $77.00K | 133.33% |
| 2019-09-30 | $33.00K | -94.87% |
| 2019-06-30 | $643.00K | 14.82% |
| 2019-03-31 | $560.00K | -90.03% |
| 2018-12-31 | $5.62M | 1.76% |
| 2018-09-30 | $5.52M | 18107.12% |
| 2018-06-30 | $30.31K | -69.18% |
| 2018-03-31 | $98.32K | -56.87% |
| 2017-12-31 | $227.97K | 130.61% |
| 2017-09-30 | $98.85K | 22.39% |
| 2017-06-30 | $80.77K | -56.04% |
| 2017-03-31 | $183.73K | 81.64% |
| 2016-12-31 | $101.15K | 19.48% |
| 2016-09-30 | $84.66K | 63.84% |
| 2016-06-30 | $51.67K | -14.43% |
| 2016-03-31 | $60.39K | -20.80% |
| 2015-12-31 | $76.25K | -51.80% |
| 2015-09-30 | $158.20K | -52.40% |
| 2015-06-30 | $332.32K | -1372.59% |
| 2015-03-31 | $-26.11K | - |
Benitec Biopharma generated - in revenue during Q1 2026, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Benitec Biopharma Revenue Breakdown
Benitec Biopharma Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Jun 23 | Jun 22 | Jun 20 |
|---|---|---|---|
| License | $75.00K | $73.00K | - |
| Grant | - | - | $5.00K |
Latest
Benitec Biopharma's latest annual revenue breakdown by segment (product or service), as of Jun 23: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 21 | Dec 20 | Sep 20 |
|---|---|---|---|
| Service | - | - | - |
| License | $1.00K | $1.00K | $55.00K |
| Royalty | - | - | - |
Latest
Benitec Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Mar 21: License (100.00%).
Benitec Biopharma Revenue Breakdown by Country
Annual Revenue by Country
| Country | Jun 22 | Jun 20 | Jun 19 |
|---|---|---|---|
| License | $73.00K | - | - |
| Grant | - | $5.00K | - |
| AUSTRALIA | - | - | $14.63M |
Latest
Benitec Biopharma's latest annual revenue breakdown by geography, as of Jun 22: License (100.00%).
Benitec Biopharma Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| XOMA | XOMA Royalty | $28.49M | $9.35M |
| IMAB | I-Mab | $27.64M | $1.10M |
| AUTL | Autolus Therapeutics | $10.12M | $21.14M |
| OCGN | Ocugen | $4.05M | $1.75M |
| PRTC | PureTech Health | $3.33M | $178.57K |
| QSI | Quantum-Si | $3.06M | $552.00K |
| SLDB | Solid Biosciences | - | - |
| NGNE | Neurogene | - | - |
| BNTC | Benitec Biopharma | - | - |
| GALT | Galectin Therapeutics | - | - |